Mark Pykett
Director/Board Member at PHARMING GROUP N.V.
Net worth: 114 989 $ as of 31/05/2024
Profile
Dr. Mark J.
Pykett is a Chairman at Inflectis Bioscience SAS and a Chairman at MyoPax GmbH.
He is on the Board of Directors at Pharming Group NV and Exubrion Therapeutics , Inc. Dr. Pykett was previously employed as a Chief Executive Officer by Myrtelle, Inc., a Chief Scientific Officer by PTC Therapeutics, Inc., a President, Chief Executive Officer & Director by Agilis Biotherapeutics LLC, a Chief Executive Officer & Director by Navidea Biopharmaceuticals, Inc., a President & Chief Operating Officer by Alseres Pharmaceuticals, Inc., a President by Life Corp.
Ltd.
(Australia), an Independent Director by Mast Therapeutics, Inc., a President by CordLife Pte Ltd., and a President & Chief Executive Officer by Cytomatrix.
He also served on the board at Oramax LLC and Health Builders International, Inc. He received his undergraduate degree from Amherst College, an MBA from Northeastern University, a doctorate degree from the University of Pennsylvania School of Veterinary Medicine and a doctorate degree from the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHARMING GROUP NV
0.02% | 29/05/2024 | 129,095 ( 0.02% ) | 114 989 $ | 31/05/2024 |
Mark Pykett active positions
| Companies | Position | Start |
|---|---|---|
| PHARMING GROUP N.V. | Director/Board Member | 11/12/2020 |
Exubrion Therapeutics , Inc.
 Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Director/Board Member | - |
Inflectis Bioscience SAS
 Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Chairman | 04/10/2021 |
MyoPax GmbH
 MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | Chairman | - |
Former positions of Mark Pykett
| Companies | Position | End |
|---|---|---|
| PTC THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Agilis Biotherapeutics LLC
 Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2018 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Chief Executive Officer | 30/05/2014 |
| ALSERES PHARMACEUTICALS, INC. | President | 04/01/2010 |
| Oramax LLC | Director/Board Member | 01/01/2006 |
Training of Mark Pykett
| University of Pennsylvania | Doctorate Degree |
| Amherst College | Undergraduate Degree |
| Northeastern University | Masters Business Admin |
| University of Pennsylvania School of Veterinary Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| ALSERES PHARMACEUTICALS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| CORDLIFE GROUP LIMITED | Health Services |
| PHARMING GROUP N.V. | Health Technology |
| Private companies | 10 |
|---|---|
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
| CyGenics Ltd. | Commercial Services |
Agilis Biotherapeutics LLC
Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Health Builders International, Inc.
 Health Builders International, Inc. Financial ConglomeratesFinance Health Builders International, Inc. is an American development stage company. | Finance |
Cytomatrix
 Cytomatrix Miscellaneous Commercial ServicesCommercial Services Part of Cordlife Group Ltd., Cytomatrix is a company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million. | Commercial Services |
| Oramax LLC | |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Health Technology |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Health Technology |
MyoPax GmbH
MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | Health Technology |
| Myrtelle, Inc. | Health Technology |
- Stock Market
- Insiders
- Mark Pykett
